- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02356991
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
A Randomized,Double-Blind, Placebo-Controlled, Multicenter, Phase II Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC).
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Shanghai, Kina, 200433
- Tongji University Affiliated Shanghai Pulmonary Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Cancer Hospital of Guangzhou Sun Yat-sen University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 1.Age: 18-70;
- 2.Advanced (IV phase)non squamous NSCLC confirmed by pathology, with measurable lesions (tumour lesions ≥10mm in longest diameter, malignant lymph nodes ≥15mm in short axis, scanning layer ≤ 5 mm, measurable lesions not received locoregional theraphy ,such as radiotherapy or frozen therapy);
3.Previously treated with EGFR inhibitors or chemotherapy,second line or above treatment failure:
- a.for EGFR wild type, second line or above treatment failure(at least previously treated with platinum-based chemotherapy)
- b.for EGFR mutation type, third line or above treatment failure(at least previously treated with Platinum-based chemotherapy and EGFR inhibitors)
- 4.ECOG Performance Status of 0 or 1;
- 5.Life expectancy of at least 3 months;
- 6.Damage caused by other anti-tumor therapy has been restored, the nitroso or mitomycin treatment interval ≥ 6 weeks; other cytotoxic drugs, radiotherapy or surgery for ≥ 4 weeks; EGFR molecular targeted drugs for ≥ 2 weeks;
7.Participants have inadequate organ and marrow function as defined below:
- Hemoglobin ≥ 90g/L ( no blood transfusion in 2 weeks)
- Absolute neutrophil count (ANC) ≥ 1.5×10^9/L
- PLT ≥ 80×10^9/L
- Bilirubin < 1.25 × ULN
- ALT < 2.5 × ULN
- AST < 2.5 × ULN
- serum creatinine < 1.25 × ULN, and endogenous Cr clearance > 45 ml/min(Cockcroft-Gault Formula)
- cholesterol ≤ 1.5×ULN and triglyceride≤ 2.5 × ULN
- LVEF≥ LLN by Color Doppler Ultrasonography
- 8.Female: Child bearing potential, a negative urine or serum pregnancy test result 7 days before initiating famitinib.All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 8 weeks after the last dose of test article. Male: All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 8 weeks after the last dose of test article;
- 9.Ability to understand and willingness to sign a written informed consent. Good compliance with follow-up visits.
Exclusion Criteria:
- 1.Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated carcinoma); small cell lung cancer (lung cancer including small cell carcinoma and non-small cell hybrid);
- 2.Known brain metastases, spinal cord compression, cancer meningitis, or screening CT or MRI examination revealed brain or leptomeningeal disease
- 3.Patients with hypertension using combination therapy (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg). Patients with more than Class I, myocardial ischemia or myocardial infarction, arrhythmia (including QT interval ≥ 450ms for male and 470ms for female) and class II cardiac dysfunction,according to NCI-CTC AE 4.0;
- 4.Variety of factors that affect the oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction);
- 5.Coagulation abnormalities (PT or PT-INR > 1.5 ULN, and APTT > 1.5 ULN), bleeding tendency (eg, active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy;
- 6.Distance between tumours lesions and major blood vessels with radiographical evidence (CT or MRI) ≥5mm.
- 7.Pulmonary hemorrhage/ bleeding event ≥ CTCAE gr. 1 (including Hemoptysis≥2.5ml or half teaspoon)within four weeks of the first dose of the study drug; Any other hemorrhage/ bleeding event ≥ CTCAE gr. 2 within four weeks of the first dose of the study drug;
- 8.Long-term untreated wounds or fractures;
- 9.Thrombotic or embolic venous or arterial events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 12 months prior to the first dose of study drug;
- 10.Urine protein ≥ + + and confirmed the 24-hour urinary protein>1.0 g;
- 11.Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) ,low-dose heparin (0.6~1.2 ×10^8 U daily) low-dose aspirin (less than 100mg daily) is allowed;
- 12.Preexisting thyroid dysfunction, even using medical therapy, thyroid function cannot maintain in the normal range;
- 13.Pre-existing ascites and/or clinically significant pleural effusion;
- 14.Active hepatitis C and/or B infection;
- 15.Abuse of psychiatric drugs or dysphrenia;
- 16.Participated in other anti-cancer clinical trials within four weeks;
- 17.Prior therapy with VEGFR inhibitor,except Bevacizumab (Avastin);
- 18.Past or suffering from other cancer, but other than cure basal cell carcinoma and cervical carcinoma in situ.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Famitinib
Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
|
|
Placebo komparator: Placebo
Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Progress free survival (PFS)
Tidsramme: 1.5 years
|
1.5 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Total overlevelse (OS)
Tidsramme: 2 år
|
2 år
|
Objektiv responsrate (ORR)
Tidsramme: 1 år
|
1 år
|
Disease Control Rate (DCR)
Tidsramme: 1 år
|
1 år
|
Livskvalitet
Tidsramme: 28-dagers syklusbesøk til sykdomsprogresjon
|
28-dagers syklusbesøk til sykdomsprogresjon
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Li Zhang, M.D., Cancer Hospital of Guangzhou Sun Yat-sen University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HR-FMTN- Ⅱ-NSCLC-MON
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ikke-småcellet lungekreft (NSCLC)
-
Children's Oncology GroupNational Cancer Institute (NCI)FullførtDiffust storcellet lymfom hos barn | Immunoblastisk storcellet lymfom i barndommen | Barndoms Burkitt lymfom | Ubehandlet akutt lymfatisk leukemi hos barn | Stage I Storcellet lymfom i barndommen | Stage I Childhood Small Noncleaved Cell Lymfom | Stage II Storcellet lymfom i barndommen | Stage II Barndom... og andre forholdForente stater
-
Incyte Biosciences International SàrlFullførtLivmorhalskreft | Hepatocellulært karsinom | Kreft i spiserøret | Eggstokkreft | Mesothelioma | Ikke-småcellet lungekreft (NSCLC) | Urotelialt karsinom | Merkel cellekarsinom | Diffust storcellet B-celle lymfom | Trippel-negativ brystkreft | Nyrecellekarsinom (RCC) | Småcellet lungekreft (SCLC) | Plateepitelkarsinom... og andre forholdForente stater
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)FullførtUspesifisert solid barndomssvulst, protokollspesifikk | Primær myelofibrose | Polycytemi Vera | Essensiell trombocytemi | Stage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom | Kronisk myelomonocytisk leukemi | Juvenil myelomonocytisk leukemi | Burkitt lymfom | Sekundær akutt myeloid... og andre forholdForente stater
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)FullførtEkstranodal marginalsone B-celle lymfom av slimhinne-assosiert lymfoid vev | Nodal Marginal Zone B-celle lymfom | Tilbakevendende voksen Burkitt lymfom | Tilbakevendende voksent diffust storcellet lymfom | Tilbakevendende voksent diffust blandet celle lymfom | Tilbakevendende voksent diffust småcellet... og andre forholdForente stater
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)FullførtPrimær myelofibrose | Polycytemi Vera | Essensiell trombocytemi | Stage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom | Tilbakevendende akutt myeloid leukemi hos voksne | Ekstranodal marginalsone B-celle lymfom av slimhinne-assosiert lymfoid vev | Nodal Marginal Zone B-celle lymfom og andre forholdForente stater, Italia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)FullførtHIV-infeksjon | Uspesifisert solid barndomssvulst, protokollspesifikk | Primær myelofibrose | Polycytemi Vera | Essensiell trombocytemi | Stage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom | Kronisk myelomonocytisk leukemi | Juvenil myelomonocytisk leukemi | Ekstranodal marginalsone... og andre forholdForente stater
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...FullførtKlarcellet nyrecellekarsinom | Kronisk myelomonocytisk leukemi | Tilbakevendende akutt myeloid leukemi hos voksne | Juvenil myelomonocytisk leukemi | Ekstranodal marginalsone B-celle lymfom av slimhinne-assosiert lymfoid vev | Nodal Marginal Zone B-celle lymfom | Tilbakevendende voksen Burkitt lymfom og andre forholdForente stater, Tyskland, Italia
Kliniske studier på Placebo
-
SamA Pharmaceutical Co., LtdUkjentAkutt bronkitt | Akutt øvre luftveisinfeksjonKorea, Republikken
-
National Institute on Drug Abuse (NIDA)FullførtCannabisbrukForente stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyFullførtMannlige personer med type II diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedFullførtFarmakokinetikk | SikkerhetsproblemerStorbritannia
-
Texas A&M UniversityNutraboltFullførtGlucose and Insulin Response
-
Regado Biosciences, Inc.FullførtFrivillig friskForente stater
-
Longeveron Inc.AvsluttetHypoplastisk venstre hjertesyndromForente stater
-
ItalfarmacoFullførtBecker muskeldystrofiNederland, Italia
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Fullført